Select Bibliography

Filter by any of these (after searching):

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 3 items

Final Results of a phase III trial of celecoxib (C) in addition to standard chemotherapy for advanced NSCLC with COX- 2 overexpression: CALGB 30801 (Alliance)

Edelman, Martin J. , Wang, Xiaofei , Hodgson, Lydia ... - MSTO - Int J Radiat Oncol Biol Phys - 2017

Abstract - Primary - Primary - Respiratory - CALGB-30801

Long-term Survival of Patients (pts) Treated with High-dose Radiotherapy(rt) and Concurrent Chemotherapy for Unresectable Non-small Cell Lung Cancer (nsclc)

Schild, S. , Hillman, S. , Graham, D. , Vora, S. , Garces, Y. ... - MSTO - J Thorac Oncol - 2012

Abstract - Primary - Long-Term-Followup - Respiratory - NCCTG-N0028

Switch Maintenance with Sunitinib (S) in Advanced Non-Small Cell Lung Cancer (NSCLC): An Alliance (CALGB 30607), Randomized, Placebo-controlled Phase III Trial

Socinski, Mark A. , Wang, Xiaofei F. , Baggstrom, Maria Quintos ... - MSTO - Int J Radiat Oncol Biol Phys - 2014

Abstract - Primary - Primary - Respiratory - CALGB-30607